Patients with neuropsychiatric medication
Conditions
Interventions
Group 1: Interventional study:
Capillary blood is collected from residents of a nursing home with neuropsychiatric pharmacotherapy via lancet puncture of the fingertip or alternatively the earlobe, u
Sponsors
Institut für Pharmazeutische und Medizinische Chemie – Klinische Pharmazie – der Universität Münster
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Use of at least one of the following psychiatric drugs: Citalopram, Clozapine, Desvenlafaxine, Escitalopram, Mirtazapine, Paliperidone, Quetiapine, Risperidone, Venlafaxine, Sertraline (2) Written informed consent
Exclusion criteria
Exclusion criteria: Palliative or pre-terminal situation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall objective: Feasibility assessment Primary endpoint: Number of plasma concentration levels (1) within, (2) below, (3) above, and (4) above the “laboratory alert level” of the therapeutic reference range (according to Hiemke et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)) Endpoint data will be collected at the time of the first capillary blood sampling. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Symptoms such as dizziness and sedation (past 7 days) (2) Cognitive function (Montreal Cognitive Assessment – short version, s-MoCA) (3) Number of falls (past 3 months) (4) Unplanned hospitalizations/emergency department visits (past 3 months) (5) Improvement of disease (Clinical Global Impression Scale – Improvement, CGI-I) (6) Experiences and satisfaction of nursing staff (semi-structured interviews) Endpoint data will be collected at the time of the first capillary blood sampling. | — |
Countries
Germany
Contacts
Public ContactGeorg Hempel
Institut für Pharmazeutische und Medizinische Chemie – Klinische Pharmazie – der Universität Münster
Outcome results
None listed